Nov 14, 2016 12:01 pm UTC| Business
Enhanced Tumor Rejection in Colorectal Cancer Mouse Model Combined Synergistically with PD1 and PD-L1 Checkpoint Inhibitors DURHAM, N.C., Nov. 14, 2016 -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the...
Nov 14, 2016 12:01 pm UTC| Business
Enhanced Tumor Rejection in Colorectal Cancer Mouse Model Combined Synergistically with PD1 and PD-L1 Checkpoint Inhibitors DURHAM, N.C., Nov. 14, 2016 -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the...
Nov 14, 2016 12:01 pm UTC| Business
PLYMOUTH MEETING, Pa., Nov. 14, 2016 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T...
Nov 14, 2016 12:01 pm UTC| Business
PLYMOUTH MEETING, Pa., Nov. 14, 2016 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T...
Nov 14, 2016 12:01 pm UTC| Business
NEW YORK, Nov. 14, 2016 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today reported encouraging preclinical efficacy for the treatment of neuropathic pain and visceral pain with their novel...
Nov 14, 2016 12:01 pm UTC| Business
NEW YORK, Nov. 14, 2016 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today reported encouraging preclinical efficacy for the treatment of neuropathic pain and visceral pain with their novel...
Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors
Nov 14, 2016 12:01 pm UTC| Business
LEXINGTON, Mass., Nov. 14, 2016 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers,...